ASCO Annual Meeting | Conference

Dr. Rodriguez-Abreu on the Final Analysis of the KEYNOTE-189 Trial in NSCLC

June 2nd 2020

Delvys Rodriguez-Abreu, MD, discusses the final analysis of the phase 3 KEYNOTE-189 study in metastatic nonsquamous non–small cell lung cancer.

Dr. Herbst on the Benefit of Adjuvant Osimertinib in EGFR-Mutant NSCLC

June 2nd 2020

Roy S. Herbst, MD, PhD, discusses the benefit of adjuvant osimertinib demonstrated in patients with stage II to IIIA EGFR-mutant non–small cell lung cancer in the phase 3 ADAURA trial.

Dr. Plimack on Updated Findings of the KEYNOTE-426 Study in RCC

June 2nd 2020

Elizabeth R. Plimack, MD, MS, discusses the updated findings from the phase 3 KEYNOTE-426 study in patients with previously untreated, advanced renal cell carcinoma.

Infigratinib Demonstrates Clinical Activity Across Settings in Urothelial Cancer

June 2nd 2020

Infigratinib was found to demonstrate clinical activity in patients with metastatic urothelial carcinoma, regardless of what line of therapy it was administered.

Pralsetinib Active Across RET+ Tumor Types and Gains FDA Review

June 1st 2020

RET inhibitor pralsetinib induced responses in a number of patients with rare and difficult to treat RET fusion–positive solid tumors.

MGD013 Demonstrates Encouraging Activity Across Tumor Types

June 1st 2020

MGD013, an investigational DART protein targeting PD-1 and LAG-3, demonstrated encouraging monotherapy activity as well as in combination with margetuximab in multiple tumor types.

Dr. Usmani on Activity of Teclistamab in Relapsed/Refractory Multiple Myeloma

June 1st 2020

Saad Usmani, MD, discusses research with teclistamab (JNJ-64007957) in relapsed/refractory multiple myeloma presented at the 2020 ASCO Virtual Scientific Program.

Alectinib Continues to Maintain Significant OS Benefit in ALK+ NSCLC

June 1st 2020

The highly selective second-generation TKI alectinib demonstrated a clinically meaningful improvement in overall survival compared with crizotinib in patients with ALK-positive non–small cell lung cancer.

Tepotinib Displays Durable Clinical Benefit in METex14-Altered NSCLC

May 31st 2020

The oral, highly selective MET inhibitor tepotinib demonstrated durable clinical activity in patients with locally advanced or metastatic non–small cell lung cancer who harbor a MET exon 14 skipping mutation identified through liquid or tissue biopsy.

Robust Data and Multivariate Analyses Support Cabazitaxel as a Standard of Care in mCRPC

May 31st 2020

The use of cabazitaxel over abiraterone acetate or enzalutamide may continue as a standard of care in men with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and either of those 2 androgen receptor-targeted agents.

Cabozantinib Plus Atezolizumab Shows Promise in mCRPC

May 31st 2020

The combination of cabozantinib and atezolizumab showed clinically meaningful activity in patients with metastatic castration-resistant prostate cancer.

Darolutamide Improves OS, Delays Onset of Cancer-Related Morbidity and Subsequent Chemo in Nonmetastatic CRPC

May 31st 2020

Darolutamide (Nubeqa) plus androgen deprivation therapy led to a 31% reduction in the risk of death compared with placebo and ADT in patients with nonmetastatic castration-resistant prostate cancer.

IMvigor010 Misses DFS End Point in Muscle-Invasive Urothelial Carcinoma

May 31st 2020

The phase 3 IMvigor010 trial comparing adjuvant atezolizumab with observation in patients with muscle-invasive urothelial carcinoma failed to meet its primary endpoint of disease-free survival.

Cabozantinib Maintains Efficacy in Advanced RCC Irrespective of Prior Treatment

May 31st 2020

Patients with advanced renal cell carcinoma who were treated with cabozantinib (Cabometyx) following both immunotherapy and non-IO regimens demonstrated promising responses.

Pyrotinib Combo Improves PFS in HER2+ Metastatic Breast Cancer

May 31st 2020

Pyrotinib plus capecitabine achieved a better progression-free survival than lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and chemotherapy.

Longer Follow-Up for Cemiplimab Confirms Superior Efficacy Over Other Regimens for CSCC

May 31st 2020

In the phase 2 trial EMPOWER-CSCC-1, up to 3 years of follow-up showed continued response rates, and a clinically meaningful survival and duration of response for cemiplimab-rwlc in patients with advanced cutaneous squamous cell carcinoma.

Baseline and Posttreatment ctDNA Positivity Linked to Poor Prognosis, rPFS in mCRPC

May 31st 2020

Baseline and posttreatment circulating tumor DNA positivity was associated with worse radiologic progression-free survival in patients with metastatic castration-resistant prostate cancer.

Frontline Pembrolizumab/Axitinib Survival Benefit Upholds in Advanced RCC

May 31st 2020

The combination of pembrolizumab and axitinib continued to demonstrate a clinically significant improvement in progression-free and overall survival compared with sunitinib in patients with previously untreated, advanced renal cell carcinoma.

Dr. Van Tine on Next Steps With ADP-A2M4 in Advanced Solid Tumors

May 31st 2020

Brian A. Van Tine, MD, PhD, discusses next steps with ADP-A2M4 SPEAR T cells in advanced solid tumors.

Tislelizumab Frontline Combos Extend PFS in Squamous NSCLC

May 31st 2020

Combining the anti–PD-1 agent tislelizumab with chemotherapy improved progression-free survival compared with chemotherapy alone as a frontline treatment in Chinese patients with advanced squamous non–small cell lung cancer.